Next Article in Journal
Clinical Importance of Drug Adherence during Tyrosine Kinase Inhibitor Therapy for Chronic Myelogenous Leukemia in Chronic Phase
Previous Article in Journal
Embolization of Bio-Alcamid Gluteal Injections in a Female Patient with Patent Foramen Ovale Leading to ARDS and Embolic Stroke
Open AccessArticle

Impacts of Different Modes of Bariatric Surgery on Plasma Levels of Hepassocin in Patients with Diabetes Mellitus

by Wen-Chi Wu 1,†, Wei-Jei Lee 2,3, Chun Yeh 4,†, Shu-Chun Chen 5 and Chih-Yen Chen 6,7,*
1
Department of Medicine, Taipei Veterans General Hospital, Taipei 11217, Taiwan
2
Department of Surgery, Min-Sheng General Hospital, Taoyuan 330, Taiwan
3
Taiwan Society for Metabolic and Bariatric Surgery, Taipei 11031, Taiwan
4
Division of Gastroenterology, Department of Internal Medicine, Cheng-Hsin General Hospital, Taipei 112, Taiwan
5
Department of Nursing, Chang-Gung Institute of Technology, Guishan, Taoyuan 333, Taiwan
6
Division of Gastroenterology and Hepatology, Department of Medicine, Taipei Veterans General Hospital, Taipei 11217, Taiwan
7
Faculty of Medicine, National Yang-Ming University School of Medicine, Taipei 11221, Taiwan
*
Author to whom correspondence should be addressed.
These authors contributed equally to this work.
Reports 2019, 2(4), 24; https://doi.org/10.3390/reports2040024
Received: 15 September 2019 / Revised: 30 September 2019 / Accepted: 30 September 2019 / Published: 5 October 2019
Background: Hepassocin is a liver-derived protein and its serum concentrations significantly increase in diabetes and fatty liver patients. Hepassocin is also a biomarker for diabetes and fatty liver; therefore, we aimed to investigate the impacts of different types of bariatric surgery on hepassocin plasma levels in obese patients with diabetes, and to determine if hepassocin could be a potential new marker for monitoring the effects of bariatric surgery and a treatment target. Methods: Overall, 12 patients undergoing gastric bypass (GB), 10 patients undergoing sleeve gastrectomy (SG) and 11 patients undergoing duodeno-jejunal bypass with sleeve gastrectomy (DJB-SG) were enrolled. Fasting hepassocin levels were measured at baseline, three, 12, and 24 months after surgery. Results: All the three groups significantly decreased their body mass index, waist-to-hip ratio, a body shape index (ABSI), triglycerides, fasting blood sugar, hemoglobin A1c, C-peptide levels and homeostasis model assessment of insulin resistance 24 months after surgery. There were no significant changes in hepassocin levels, even 24 months after the three surgeries. Hepassocin had a significant negative relationship with the ABSI (p< 0.001) 24 months after the SG. Conclusions: Neither GB, SG, nor DJB-SG altered plasma hepassocin levels in diabetic patients up to 24 months after surgery. The use of hepassocin in clinical settings requires more investigation. View Full-Text
Keywords: hepassocin; gastric bypass (GB); sleeve gastrectomy (SG); duodeno-jejunal bypass with sleeve gastrectomy (DJB-SG); type 2 diabetes mellitus (T2DM) hepassocin; gastric bypass (GB); sleeve gastrectomy (SG); duodeno-jejunal bypass with sleeve gastrectomy (DJB-SG); type 2 diabetes mellitus (T2DM)
Show Figures

Figure 1

MDPI and ACS Style

Wu, W.-C.; Lee, W.-J.; Yeh, C.; Chen, S.-C.; Chen, C.-Y. Impacts of Different Modes of Bariatric Surgery on Plasma Levels of Hepassocin in Patients with Diabetes Mellitus. Reports 2019, 2, 24.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop